



Amarin Neuroscience Ltd
First Floor, Block 3, The Oval
Shelbourne Road
Ballsbridge, Dublin 4
Ireland

December 1st 2009

Dr Eric Abadie
European Medicines Agency
7 Westferry Circus
Canary Wharf
London
E14 4HB

**Re: Withdrawal of Ethyl Eicosapent Soft Capsules, 500 mg (INN: Ethyl Eicosapent),
EMA/H/C/001148/0000**

Dear Dr Eric Abadie,

I am writing to inform you that we, the Applicant, Amarin Neuroscience Ltd, have taken the decision at this point in time to withdraw the application for Marketing Authorisation of Ethyl Eicosapent Soft Capsules, 500 mg (INN: Ethyl Eicosapent), which was intended to be used for the long -term stabilisation of symptoms in patients with Huntington's disease.

Amarin has taken this decision on the basis of preliminary comments from the Rapporteur and Co-Rapporteur which indicate that CHMP is unlikely to conclude a favorable approval decision without additional efficacy support.

The Company intends to continue the development of this product for other indications.

We reserve the right to make further submissions at a future date in this or other therapeutic indication(s).

I agree for this letter to be published on the EMA website.

Please do not hesitate to contact me if you require any further information.